Page 125 - Haematologica3

Blood cytokine concentrations in ALK-positive ALCL
of cytokines in clinical manifestations. Leuk
Lymphoma. 2001;40(5-6):599-611.
12. Janik JE, Morris JC, Pittaluga S, et al. Elevated serum-soluble interleukin-2 recep- tor levels in patients with anaplastic large cell lymphoma. Blood. 2004;104(10):3355-
3357.
13. Nadali G, Vinante F, Stein H, et al. Serum
levels of the soluble form of CD30 mole- cule as a tumor marker in CD30+ anaplas- tic large-cell lymphoma. J Clin Oncol. 1995;13(6):1355-1360.
14. Zinzani PL, Pileri S, Bendandi M, et al. Clinical implications of serum levels of sol- uble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol. 1998;16(4):1532-1537.
15. Qiu L, Lai R, Lin Q, et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lym- phoma cells. Blood. 2006;108(7):2407-2415.
16. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation con- tribute to tumorigenicity in ALK+ anaplas- tic large cell lymphoma. Leukemia. 2008;22(8):1595-1603.
17. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma- type chemotherapy is efficacious treatment for pediatric anaplastic large cell lym- phoma: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-3706.
18. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110(2):670-677.
19. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pedi- atric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood.
2010;115(16):3314-3319.
20. Mussolin L, Damm-Welk C, Pillon M, et al.
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27(2):416-422.
21. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of sol- uble Ki-1 antigen and detection of the anti- gen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989;19(1):157-162.
22. Miles RR, Cairo MS, Satwani P, et al. Immunophenotypic identification of possi- ble therapeutic targets in paediatric non- Hodgkin lymphomas: a Children's Oncology Group report. Br J Haematol. 2007;138 (4):506-512.
23. Matsuyama H, Suzuki HI, Nishimori H, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011;118(26):6881- 6892.
24. Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prog- nosis. Int J Cancer. 2002;100(4):463-471.
25. Bien E, Balcerska A. Serum soluble inter- leukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 2008;13(1):1-26.
26. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218-228.
nize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol. 2006;77(5):387-394.
29. Damm-Welk C, Pillon M, Woessmann W, Mussolin L. Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK. Front Biosci (Schol Ed). 2015;7:205-216.
30. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.
31. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 pro- motes a distinct CD4 T cell activation state characterized by the production of inter- leukin-17. J Biol Chem. 2003;278(3):1910- 1914.
32. Croxford AL, Mair F, Becher B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol. 2012;42(9):2263-2273.
33. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232-4244.
34. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA. 2006;103(26):9964-9969.
35. Farber JM. A macrophage mRNA selective- ly induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci USA. 1990;87(14):5238-5242.
36. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plas- ticity. Curr Opin Immunol. 2012;24(3):297-
27. Gupta M, Stenson M, O'Byrne M, et al. Comprehensive serum cytokine analysis
identifies IL-1RA and soluble IL-2Ralpha as 302.
predictors of event-free survival in T-cell lymphoma. Ann Oncol. 2016;27(1):165- 172.
28. Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recog-
37. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560-1566.
haematologica | 2018; 103(3)
485